The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State.

PURPOSE The Maine Cancer Genomics Initiative (MCGI) aimed to overcome patient- and provider-level barriers to using genomic tumor testing (GTT) in rural practices by providing genomic tumor boards (GTBs), clinician education, and access to comprehensive large-panel next-generation sequencing to all patients with cancer in Maine. This paper describes the successful implementation of the initiative and three key services made operative between 2016 and 2020. METHODS A community-inclusive, hub-and-spoke approach was taken to implement the three program components: (1) a centralized GTB program; (2) a modular online education program, designed using an iterative approach with broad clinical stakeholders; and (3) GTT free of charge to clinicians and patients. Implementation timelines, participation metrics, and survey data were used to describe the rollout. RESULTS The MCGI was launched over an 18-month period at all 19 oncology practices in the State. Seventy-nine physicians (66 medical oncologists, 5 gynecologic oncologists, 1 neuro-oncologist, and 7 pediatric oncologists) enrolled on the study, representing 100% of all practicing oncologists in Maine. Between July 2017 and September 2020, 1610 patients were enrolled. A total of 515 cases were discussed by 47 (73%) clinicians in 196 GTBs. Clinicians who participated in the GTBs enrolled significantly more patients on the study, stayed in Maine, and reported less time spent in clinical patient care. CONCLUSION The MCGI was able to engage geographically and culturally disparate cancer care practices in a precision oncology program using a hub-and-spoke model. By facilitating access to GTT, structured education, and GTBs, we narrowed the gap in the implementation of precision oncology in one of the most rural states in the country.

[1]  Katherine M. Tucker,et al.  Genetic and genomic learning needs of oncologists and oncology nurses in the era of precision medicine: a scoping review. , 2022, Personalized medicine.

[2]  G. Ananda,et al.  RNA-Seq for the detection of gene fusions in solid tumors: development and validation of the JAX FusionSeq™ 2.0 assay , 2022, Journal of Molecular Medicine.

[3]  David M. Thomas,et al.  Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions , 2021, Public Health Genomics.

[4]  Karen E. Rasmussen,et al.  Community oncologists’ perceptions and utilization of large-panel genomic tumor testing , 2021, BMC Cancer.

[5]  Sanjeev Arora,et al.  Project ECHO Cancer Initiative: a Tool to Improve Care and Increase Capacity Along the Continuum of Cancer Care , 2021, Journal of Cancer Education.

[6]  F. Huang,et al.  Global Precision Oncology: A Call to Action on Expanding Access to Targeted Cancer Therapies. , 2021, The oncologist.

[7]  J. Godino,et al.  Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center , 2020, Hepatology communications.

[8]  P. Han,et al.  Differences in cancer patients' and clinicians' preferences for disclosure of uncertain genomic tumor testing results. , 2020, Patient education and counseling.

[9]  T. Strout,et al.  The influence of uncertainty and uncertainty tolerance on attitudes and self-efficacy about genomic tumor testing , 2020, Psychology, health & medicine.

[10]  S. Patterson,et al.  Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data , 2019, npj Precision Oncology.

[11]  Lincoln D Nadauld,et al.  Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions. , 2018, Health affairs.

[12]  L. Nadauld,et al.  Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs , 2018, Oncotarget.

[13]  S. Sleijfer,et al.  Molecular Tumor Boards: current practice and future needs , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. McLeod,et al.  Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off‐Label Drug Use , 2017, Pharmacotherapy.

[15]  Howard L. McLeod,et al.  Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. , 2017, The oncologist.